Payment overview · 2025
General Payments
$390.71
21 reported records · 6 companies
Healthcare provider profile · identity verified
Hoe Le, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SANTEE, CA · NPI 1811945611
Verified facts
What the public records show
CMS Open Payments records show Hoe Le, M.D. received $390.71 in general payments during 2025 across 21 reported records.
Kowa Pharmaceuticals America, Inc. accounted for 39.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexium by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $153.31 | 39.2% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $79.75 | 20.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.12 | 13.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $42.05 | 10.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.60 | 9.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.88 | 5.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $390.71 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $153.31 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.12 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $54.12 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $42.05 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $32.20 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $32.20 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $32.20 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $27.67 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $22.88 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
119 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 651 | 173 |
| Omeprazole | Omeprazole | 352 | 80 |
| Metformin Hcl | Metformin Hcl | 350 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 330 | 79 |
| Lisinopril | Lisinopril | 321 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 289 | 71 |
| Simvastatin | Simvastatin | 252 | 65 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 200 | 120 |
| Pantoprazole Sodium | Pantoprazole Sodium | 182 | 45 |
| Losartan Potassium | Losartan Potassium | 175 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 167 | 48 |
| Trazodone Hcl | Trazodone Hcl | 165 | 37 |
| Gabapentin | Gabapentin | 150 | 35 |
| Glipizide | Glipizide | 138 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 134 | 60 |
| Baclofen | Baclofen | 128 | 27 |
| Furosemide | Furosemide | 127 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 30 |
| Jardiance | Empagliflozin | 119 | 26 |
| Alprazolam | Alprazolam | 118 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 117 | 25 |
| Ibuprofen | Ibuprofen | 116 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 20 |
| Montelukast Sodium | Montelukast Sodium | 94 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 90 | 21 |
| Sertraline Hcl | Sertraline Hcl | 90 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 89 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 86 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 16 |
| Ezetimibe | Ezetimibe | 78 | 21 |
| Cephalexin | Cephalexin | 76 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 72 | 21 |
| Carvedilol | Carvedilol | 69 | 19 |
| Potassium Chloride | Potassium Chloride | 69 | 19 |
| Januvia | Sitagliptin Phosphate | 64 | suppressed |
| Atenolol | Atenolol | 63 | 14 |
| Allopurinol | Allopurinol | 61 | 16 |
| Bupropion Xl | Bupropion Hcl | 61 | 12 |
| Eliquis | Apixaban | 61 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 15 |
| Famotidine | Famotidine | 57 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 56 | 14 |
| Naproxen | Naproxen | 54 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 12 |
| Azithromycin | Azithromycin | 50 | 28 |
| Benazepril Hcl | Benazepril Hcl | 49 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 49 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 11 |
| Lovastatin | Lovastatin | 40 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Estradiol | Estradiol | 39 | suppressed |
| Meloxicam | Meloxicam | 39 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Prednisone | Prednisone | 37 | suppressed |
| Nystatin | Nystatin | 36 | 13 |
| Donepezil Hcl | Donepezil Hcl | 35 | suppressed |
| Olanzapine | Olanzapine | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 29 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Acyclovir | Acyclovir | 27 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 13 |
| Moxifloxacin | Moxifloxacin Hcl | 20 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 13 |
| Livalo | Pitavastatin Calcium | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 11 |
| Ozempic | Semaglutide | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Entecavir | Entecavir | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Nexium | Esomeprazole Magnesium | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Semglee (Yfgn) | Insulin Glargine-Yfgn | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $390.71 · 21 records | Kowa Pharmaceuticals America, Inc. | ABRYSVO, AIRSUPRA, COMIRNATY, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, Rybelsus, Saxenda, TRELEGY ELLIPTA, VYNDAQEL, Wegovy, ZAVZPRET, ZEPBOUND, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error